A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)

Trial Identifier: D3614C00007
Sponsor: AstraZeneca
Collaborator:
Quotient Sciences Ltd
NCTID:: NCT05419401
Start Date: April 2022
Primary Completion Date: July 2022
Study Completion Date: July 2022
Condition: Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
English (UK) Translation

Trial Locations